New opportunities for allergen immunotherapy using synthetic peptide immuno-regulatory epitopes (SPIREs)

References

• Scadding GK. Optimal management of allergic rhinitis. Arch Dis Child. 2015;100(6):576–582.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 Update. Allergy. 2008;63(s86):8–160.
   PubMed Web of Science ®Google Scholar
• Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: complete guidelines of the joint task force on practice parameters in allergy, asthma and immunology. American academy of allergy, asthma, and immunology. Ann Allergy Asthma Immunol. 1998;81(5 pt 2):478–518.
   PubMed Web of Science ®Google Scholar
• Berger WE. Overview of allergic rhinitis. Ann Allergy Asthma Immunol. 2003;90(6 suppl 3):7–12.
   PubMed Web of Science ®Google Scholar
• Skoner DP. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol. 2001;108(1 suppl):S2–S8.
   PubMed Web of Science ®Google Scholar
• Arbes SJ Jr., Gergen PJ, Elliott L, et al. Prevalences of positive skin test responses to 10 common allergens in the US population: results from the third national health and nutrition examination survey. J Allergy Clin Immunol. 2005;116(2):377–383.
   PubMed Web of Science ®Google Scholar
• Rolland JM, Prickett S, Gardner LM, et al. T cell targeted strategies for improved efficacy and safety of specific immunotherapy for allergic disease. Antiinflamm Antiallergy Agents Med Chem. 2013;12(3):201–222.
   PubMedGoogle Scholar
• Creticos PS. Advances in synthetic peptide immuno-regulatory epitopes. World Allergy Organ J. 2014;7(1):30.
   PubMedGoogle Scholar
• Jutel M, Agache I, Bonini S, et al. International consensus on allergy immunotherapy. J Allergy Clin Immunol. 2015;136(3):556–568.
   PubMed Web of Science ®Google Scholar
• Pfaar O, Bachert C, Bufe A, et al. Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (OGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto- Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German Respiratory Society (DGP), the German Association of ENT Surgeons (BV-HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the German Dermatologists Association (BVDD). Allergo J Int. 2014;23(8):282–319.
   PubMedGoogle Scholar
• Senna GE, Calderon M, Milani M. Allergy immunotherapy tablet: Grazax® for the treatment of grass pollen allergy. Expert Rev Clin Immunol. 2011;7(1):21–27.
   PubMed Web of Science ®Google Scholar
• Li JT, Bernstein DI, Calderon MA, et al. Sublingual grass and ragweed immunotherapy: clinical considerations—a PRACTALL consensus report. J Allergy Clin Immunol. 2016;137(2):369–376.
   PubMed Web of Science ®Google Scholar
• Ragwitek™ (short ragweed pollen allergen extract) tablet for sublingual use [prescribing information]. Whitehouse Station, NJ: Merck & Co; 2014.
   Google Scholar
• Oralair^® (sweet vernal, orchard, perennial rye, timothy, and Kentucky blue grass mixed pollens allergen extract) tablet for sublingual use [prescribing information]. Antony, France: Stallergenes SA; 2014.
   Google Scholar
• Grastek^® (timothy grass pollen allergen extract) tablet for sublingual use [prescribing information]. Whitehouse Station, NJ: Merck & Co; 2014.
   Google Scholar
• Calderón MA, Simons FE, Malling HJ, et al. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. Allergy. 2012;67(3):302–311.
   PubMed Web of Science ®Google Scholar
• Passalacqua G, Musarra A, Pecora S, et al. Quantitative assessment of the compliance with once-daily sublingual immunotherapy in children (EASY project: evaluation of a novel SLIT formulation during a year). Pediatr Allergy Immunol. 2007;18(1):58–66.
   PubMed Web of Science ®Google Scholar
• Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy and immune tolerance to allergens. World Allergy Organ J. 2015;8(1):17.
   PubMed Web of Science ®Google Scholar
• Francis JN, James LK, Paraskevopoulos G, et al. Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J Allergy Clin Immunol. 2008;121(5):1120–1125.e2.
   PubMed Web of Science ®Google Scholar
• Sandrini A, Rolland JM, O’Hehir RE. Current developments for improving efficacy of allergy vaccines. Expert Rev Vaccines. 2015;14(8):1073–1087.
   PubMed Web of Science ®Google Scholar
• Akdis CA. Therapies for allergic inflammation: refining strategies to induce tolerance. Nat Med. 2012;18(5):736–749.
   PubMed Web of Science ®Google Scholar
• Moingeon P. Will allergen fusion bring new energy to immunotherapy. Int Arch Allergy Immunol. 2015;168(2):107–109.
   PubMed Web of Science ®Google Scholar
• Curin M, Weber M, Thalhamer T, et al. Hypoallergenic derivatives of Fel d 1 obtained by rational reassembly for allergy vaccination and tolerance induction. Clin Exp Allergy. 2014;44(6):882–894.
   PubMed Web of Science ®Google Scholar
• Huang F-Y, Wang C-C, Huang Y-H, et al. Antigen 43/Fcε3 chimeric protein expressed by a novel bacterial surface expression system as an effective asthma vaccine. Immunology. 2014;143(2):230–240.
   PubMed Web of Science ®Google Scholar
• Schmitz N, Dietmeier K, Bauer M, et al. Displaying Fel d1 on virus-like particles prevents reactogenicity despite greatly enhanced immunogenicity: a novel therapy for cat allergy. J Exp Med. 2009;206(9):1941–1955.
   PubMed Web of Science ®Google Scholar
• Niespodziana K, Focke-Tejkl M, Linhart B, et al. A hypoallergenic cat vaccine based on Fel d 1-derived peptides fused to hepatitis B PreS. J Allergy Clin Immunol. 2011;127(6):1562–70e6.
   PubMed Web of Science ®Google Scholar
• Rosewich M, Chulze J, Eickmeier O, et al. Tolerance induction after specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A in children. Clin Exp Immunol. 2010;160(3):403–410.
   PubMed Web of Science ®Google Scholar
• Fujimura T, Fujinami K, Ishikawa R, et al. Recombinant fusion allergens, Cry j 1 and Cry j 2 from Japanese cedar pollen, conjugated with polyethylene glycol potentiate the attenuation of Cry j 1-specific IgE production in Cry j 1-sensitized mice and Japanese cedar pollen allergen-sensitized monkeys. Int Arch Allergy Immunol. 2015;168(1):32–43.
   PubMed Web of Science ®Google Scholar
• Lin LH, Zheng P, Yuen JW, et al. Prevention and treatment of allergic inflammation by an Fcgamma-Der f2 fusion protein in a murine model of dust mite-induced asthma. Immunol Res. 2012;52(3):276–283.
   PubMed Web of Science ®Google Scholar
• Zhu D, Kepley CL, Zhang K, et al. A chimeric human-cat fusion protein blocks cat-induced allergy. Nat Med. 2005;11(4):446–449.
   PubMed Web of Science ®Google Scholar
• Worm M, Lee HH, Kleine-Tebbe J, et al. Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy. J Allergy Clin Immunol. 2011;127(1):89–97, 97 e1–14.
   Web of Science ®Google Scholar
• Larché M. Mechanisms of peptide immunotherapy in allergic airways disease. Ann Am Thorac Soc. 2014;11(suppl 5):S292–S296.
   PubMedGoogle Scholar
• Prickett SR, Rolland JM, O’Hehir RE. Immunoregulatory T cell epitope peptides: the new frontier in allergy therapy. Clin Exp Allergy. 2015;45(6):1015–1026.
   PubMed Web of Science ®Google Scholar
• Hafner R Synthetic Peptide Immuno-Regulatory Epitopes - A New Class of Compounds. Presented at: Global Technology Community 2nd Allergy and Respiratory Drug Discovery. San Diego, CA. 2013 January 31–February 1. Available at: https://www.gtcbio.com/preview/allergy/slides/hafner_rod.pdf.
   Google Scholar
• Creticos P, Hebert J, for the Allervax® Ragweed Study Group. Efficacy of Allervax® Ragweed peptides in the treatment of ragweed-induced allergy. J Allergy Clin Immunol. 1997;99(1pt 2):S401. Abstract 1631.
   Google Scholar
• Nicodemus C, Philip G, Jones N, et al. Integrated clinical experience with tolerogenic peptides. Int Arch Allergy Immunol. 1997;113(1–3):326–328.
   PubMed Web of Science ®Google Scholar
• Norman PS, Ohman JL Jr, Long AA, et al. Treatment of cat allergy with T-cell reactive peptides. Am J Respir Crit Care Med. 1996;154(6 pt 1):1623–1628.
   PubMed Web of Science ®Google Scholar
• Maguire P, Nicodemus C, Robinson D, et al. The safety and efficacy of ALLERVAX CAT in cat allergic patients. Clin Immunol. 1999;93(3):222–231.
   PubMed Web of Science ®Google Scholar
• Täumer T, Klimek L, Pfaar O. Die (allergen-)spezifische immuntherapie bei allergien auf tiere. Allergologie. 2016;39. doi:10.5414/ALX01846.
   Web of Science ®Google Scholar
• Program for appropriate technology in health. Intradermal delivery of vaccines: a review of the literature and the potential for development for use in low- and middle-income countries. Seattle, WA: World Health Organization; 2009. p. 1–94.
   Google Scholar
• Oldfield WL, Larché KAB. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet. 2002;360(9326):47–53.
   PubMed Web of Science ®Google Scholar
• Campbell JD, Buckland KF, McMillan SJ, et al. Peptide immunotherapy in allergic asthma generates IL-10-dependent immunological tolerance associated with linked epitope suppression. J Exp Med. 2009;206(7):1535–1547.
   PubMed Web of Science ®Google Scholar
• Berkowitz RB, Braker S, Lutz C, et al. Efficacy of fexofenadine in the prophylactic control of cat allergen-induced allergic rhinitis. Ann Allergy Asthma Immunol. 2006;96(2):327–333.
   PubMed Web of Science ®Google Scholar
• Sarpong SB, Karrison T. Skin test reactivity to indoor allergens as a marker of asthma severity in children with asthma. Ann Allergy Asthma Immunol. 1998;80(4):303–308.
   PubMed Web of Science ®Google Scholar
• Gronlund H, Saarne T, Gafvelin G, et al. The major cat allergen, Fel d 1, in diagnosis and therapy. Int Arch Allergy Immunol. 2010;151(4):265–274.
   PubMed Web of Science ®Google Scholar
• Hedlin G, Graff-Lonnevig V, Heilborn H, et al. Immunotherapy with cat- and dog-dander extracts. V. Effects of 3 years of treatment. J Allergy Clin Immunol. 1991;87(5):955–964.
   PubMed Web of Science ®Google Scholar
• Mellerup MT, Hahn GW, Poulsen LK, et al. Safety of allergen-specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side-effects during induction treatment. Clin Exp Allergy. 2000;30:1423–1429.
   PubMed Web of Science ®Google Scholar
• Worm M, Patel D, Creticos PS. Cat peptide antigen desensitisation for treating cat allergic rhinoconjunctivitis. Exp Opin Invest Drugs. 2013;22(10):1347–1357.
   PubMed Web of Science ®Google Scholar
• Walker SM, Pajno GB, Lima MT, et al. Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial. J Allergy Clin Immunol. 2001;107(1):87–93.
   PubMed Web of Science ®Google Scholar
• Day JH, Horak F, Briscoe MP, et al. The role of allergen challenge chambers in the evaluation of anti-allergic medication: an international consensus paper. Clin Exp Allergy Rev. 2006;6(2):31–59.
   Google Scholar
• Salapatek A, Patel P, Shah C, et al. An environmental exposure chamber (EEC)-specific rhinoconjunctivitis quality of life questionnaire: the symptoms of seasonal allergic rhinitis correlate with the quality of life (QOL) of patients with ragweed allergy in the EEC. Allergy Asthma Clin Immunol. 2007;3:85.
   Google Scholar
• Devillier P, Le Gall M, Horak F. The allergen challenge chamber: a valuable tool for optimizing the clinical development of pollen immunotherapy. Allergy. 2011;66(2):163–169.
   PubMed Web of Science ®Google Scholar
• Hafner RP, Patel P, Salapatek A, et al. Immunotherapy–2067. Fel d 1 peptide antigen desensitization safety and efficacy in a double-blind, placebo-controlled environmental exposure chamber study. World Allergy Organ J. 2013;6(suppl 1):P150.
   Google Scholar
• Patel D, Couroux P, Hickey P, et al. Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study. J Allergy Clin Immunol. 2013;131(1):103–9.e1–e7.
   Web of Science ®Google Scholar
• Couroux P, Patel D, Armstrong K, et al. Fel d 1-derived synthetic peptide immuno-regulatory epitopes show a long-term treatment effect in cat allergic subjects. Clin Exp Allergy. 2015;45(5):974–981.
   PubMed Web of Science ®Google Scholar
• Varney VA, Edwards J, Tabbah K, et al. Clinical efficacy of specific immunotherapy to cat dander: a double-blind placebo-controlled trial. Clin Exp Allergy. 1997;27(8):860–867.
   PubMed Web of Science ®Google Scholar
• Patel D, Bernstein, D I Plunkett G, et al. Tolerability and efficacy of sublingual immunotherapy in cat allergic subjects studies in an environmental exposure chamber. Ann Allergy Asthma Immunol. 2011;107(5 suppl):A105.
   Google Scholar
• Powell J, Haumann B, Hafner R. CAT-PAD, the first in a new class of synthetic peptide immuno-regulatory epitopes, demonstrates a favourable tolerability profile in patients with cat-induced rhinoconjunctivitis. Poster Discussion Sessions. Allergy. 2013;68(suppl97):115–188.
   Google Scholar
• Demoly P, Emminger W, Rehm D, et al. Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: results from a randomized, double-blind, placebo-controlled phase III trial. Allergy Clin Immunol. 2016;137(2):444–51.e8.
   Google Scholar
• Larché M, Hickey P, Hebert J, et al. Safety and tolerability of escalating doses of house dust mite- peptide antigen desensitization (HDM-PAD). J Allergy Clin Immunol. 2013;131(2):AB37.
   Google Scholar
• Thomas WR. Hierarchy and molecular properties of house dust mite allergens. Allergol Int. 2015;64(4):304–311.
   PubMed Web of Science ®Google Scholar
• Platts-Mills TA, Chapman MD. Dust mites: immunology, allergic disease, and environmental control. J Allergy Clin Immunol. 1987;80(6):755–775.
   PubMed Web of Science ®Google Scholar
• Hafner R, Salapatek AM, Larché M, et al. Comparison of the treatment effect of house dust mite synthetic peptide immuno-regulatory epitopes in the environmental exposure chamber and field setting two years after a short course of treatment. Allergy. 2015;70(suppl 101):1–106.
   Google Scholar
• Biagtan M, Viswanathan R, Bush K. Immunotherapy for house dust mite sensitivity: where are the knowledge gaps? Curr Allergy Asthma Rep. 2014;14(12):482.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Lockey R, Malling H-J. Allergen immunotherapy: therapeutic vaccines for allergic diseases A WHO position paper. J Allergy Clin Immunol. 1998;102(4 pt 1):558–582.
   PubMed Web of Science ®Google Scholar
• Calderon MA, Casale TB, Nelson HS, et al. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies. J Allergy Clin Immunol. 2013;132(6):1322–1336.
   PubMed Web of Science ®Google Scholar
• Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev. 2010;8:CD001186.
   PubMed Web of Science ®Google Scholar
• Canonica GW, Bousquet J, Casale T, et al. Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy. 2009;64(suppl 91):1–59.
   PubMed Web of Science ®Google Scholar
• Moldaver DM, Bharhani MS, Wattie JN, et al. Amelioration of ovalbumin-induced allergic airway disease following Der p 1 peptide immunotherapy is not associated with induction of IL-35. Mucosal Immunol. 2014;7(2):379–390.
   PubMed Web of Science ®Google Scholar
• Hafner RP, Larché M, Laidler P, et al. Mechanisims of asthma and allergic disease–1085. Safety and tolerability of escalating doses of house dust mite peptide antigen desensitisation. World Allergy Organ J. 2013;6(suppl 1):P81.
   Google Scholar
• Hafner R, Couroux P, Armstrong K, et al. Four doses of Der p derived synthetic peptide immuno-regulatory epitopes over 3 months results in a persistent treatment effect at one year on symptoms of house dust mite allergy. Allergy. 2014;69(suppl 99):1–96.
   Google Scholar
• Hafner R, Salapatek AM, Larché M, et al. Initial evidence of sustained efficacy of house dust mite synthetic peptide immunoregulatory epitopes 2 years after a short course of treatment in house dust mite (HDM) allergic subjects. J Allergy Clin Immunol. 2015;135(2):AB142.
   Google Scholar
• Linhart B, Focke-Tejkl M, Weber M, et al. Molecular evolution of hypoallergenic hybrid proteins for vaccination against grass pollen allergy. J Immunol. 2015;194(8):4008–4018.
   PubMed Web of Science ®Google Scholar
• Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med. 1999;341(7):468–475.
   PubMed Web of Science ®Google Scholar
• Di Bona D, Plaia A, Leto-Barone MS, et al. Efficacy of grass pollen allergen sublingual immunotherapy tablets for seasonal allergic rhinoconjunctivitis: a systematic review and meta-analysis. JAMA Intern Med. 2015;175(8):1301–1309.
   PubMed Web of Science ®Google Scholar
• Durham, SR, Emminger, W, Kapp, A. et al. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol. 2010;125(1):131–8 e1–7.
   PubMed Web of Science ®Google Scholar
• Durham SR, Emminger W, Kapp A, et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol. 2012;129(3):717–25 e5.
   PubMed Web of Science ®Google Scholar
• Ellis A, Frankish C, Armstrong K, et al. A short course of synthetic peptide immuno-regulatory epitopes derived from grass allergens leads to a reduction in grass allergy symptoms. Allergy. 2014;69(suppl 99):1–96.
   Google Scholar
• Ellis A, Frankish C, Armstrong K, et al. Persistent treatment effect with grass synthetic peptide immuno-regulatory epitopes (Grass-SPIRE) on grass allergy symptoms in the environmental exposure unit after a third season of natural exposure. Allergy. 2015;70(suppl. 101):1–106.
   Google Scholar
• Ellis AK, Frankish CW, Armstrong K, et al. Treatment with synthetic peptide immuno-regulatory epitopes derived from grass allergens leads to a substantial reduction in grass allergy symptoms in the environmental exposure unit. J Allergy Clin Immunol. 2014;133(2):AB290.
   Google Scholar
• Ellis A, Frankish CW, Armstrong K, et al. Persistent treatment effect with grass synthetic peptide immuno-regulatory epitopes in grass allergy symptoms in an environmental exposure unit challenge after a second season of natural pollen exposure. J Allergy Clin Immunol. 2015;135(2):AB158.
   Web of Science ®Google Scholar
• Hafner RP, Salapatek A, Patel D, et al. Validation of peptide immunotherapy as a new approach in the treatment of allergic rhinoconjunctivitis: the clinical benefits of treatment with amb a 1 derived T cell epitopes. J Allergy Clin Immunol. 2012;129(2 supplement):AB368.
   Google Scholar
• Frew AJ. Allergen immunotherapy. J Allergy Clin Immunol. 2010;125(2suppl 2):S306–S313.
   Google Scholar
• Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011;127(1 suppl):S1–S55.
   PubMed Web of Science ®Google Scholar
• Hickey PLC, Cheema AS, Larché M, et al. Safety and tolerability of Fel d 1-derived peptide antigen desensitization in subjects with controlled asthma. J Allergy Clin Immunol. 2013;131(2):AB206.
   Google Scholar
• Pawsey S, Patel D, Hafner R, et al. Safety of house dust mite synthetic peptide immuno regula btory epitopes in patients with house dust mite (HDM) allergy and controlled asthma. J Allergy Clin Immunol. 2015;133(2):AB142.
   Google Scholar
• Cappella A, Durham SR. Allergen immunotherapy for allergic respiratory diseases. Hum Vaccin Immunother. 2012;8(10):1499–1512.
   PubMed Web of Science ®Google Scholar
• Ott H, Sieber J, Brehler R, et al. Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study. Allergy. 2009;64(9):1394–1401.
   PubMed Web of Science ®Google Scholar
• Marogna M, Spadolini I, Massolo A, et al. Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. J Allergy Clin Immunol. 2010;126(5):969–975.
   PubMed Web of Science ®Google Scholar